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Introduction Literature on influenza focuses on influenza A,
despite influenza B having a large public health impact. The
Global Influenza B Study aims to collect information on global
epidemiology and burden of disease of influenza B since 2000.
Methods Twenty-six countries in the Southern (n = 5) and
Northern (n = 7) hemispheres and intertropical belt (n = 14)
provided virological and epidemiological data. We calculated the
proportion of influenza cases due to type B and Victoria and
Yamagata lineages in each country and season; tested the correlation
between proportion of influenza B and maximum weekly influenza-
like illness (ILI) rate during the same season; determined the
frequency of vaccine mismatches; and described the age distribution
of cases by virus type.
Results The database included 935 673 influenza cases (2000–
2013). Overall median proportion of influenza B was 226%, with no
statistically significant differences across seasons. During seasons
where influenza B was dominant or co-circulated (>20% of total
detections), Victoria and Yamagata lineages predominated during
64% and 36% of seasons, respectively, and a vaccine mismatch was
observed in25% of seasons. Proportion of influenza B was inversely
correlated with maximum ILI rate in the same season in the Northern
and (with borderline significance) Southern hemispheres. Patients
infected with influenza B were usually younger (5–17 years) than
patients infected with influenza A.
Conclusion Influenza B is a common disease with some
epidemiological differences from influenza A. This should be
considered when optimizing control/prevention strategies in different
regions and reducing the global burden of disease due to influenza.
Keywords Burden of disease, epidemiology, Global Influenza B
Study (GIBS), influenza, vaccination, vaccine mismatch.
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Introduction
Seasonal influenza epidemics impose a heavy burden on
society, with 3–5 million cases and 250 000–500 000 deaths
worldwide every year.1 The resulting economic impact is
large and includes both direct and indirect costs.2,3 Tradi-
tionally, attention has been directed toward influenza A,
which accounts for the majority of influenza cases in most
seasons4–6; its subtypes are also responsible for influenza
pandemics.7 During interpandemic periods, however, influ-
enza B can represent a considerable proportion of total
cases.8 Since the 1970s, influenza B viruses have belonged to
two antigenically distinct lineages called the Victoria and
Yamagata lineages9; this has been a challenge for seasonal
influenza vaccines as only one influenza B strain is included
in the trivalent vaccine. Studies in the United States have
shown that the frequent influenza B vaccine mismatches of
recent years have been associated with substantial increases in
cases, hospitalizations and deaths (up to annual 970 000
cases, with 8200 hospitalizations and 485 deaths, in the
USA),10 as well as with large influenza-related medical costs,
and costs associated with productivity loss.11
Despite the important role of influenza B, much of the
published scientific literature regarding the epidemiology of
influenza has focused on influenza A, and we still have a
relatively poor understanding of global epidemiology and
burden of disease of influenza B, especially outside Europe
and the United States.8 Several studies have reported on the
burden of disease attributable to influenza B in a single
season, or during consecutive seasons in a single country,12,13
but only one study thus far has looked at the global
epidemiology of influenza B.4 In particular, it is very
important to assess the epidemiology of influenza in the
tropics, as this is where approximately 40% of the world’s
population live,14 and influenza activity there is quite
different from other world regions15,16: countries in the
tropics may experience two annual peaks, and epidemics are
not as short and intense as in the Northern and Southern
hemispheres.17–19 These differences can have important
implications for effective and evidence-based decisions
regarding the composition and period of administration of
influenza vaccines.
The Global Influenza B Study
The Global Influenza B Study (GIBS) was launched in 2012
with the main aim of collecting information on the
epidemiology and global burden of disease of influenza B
during the past 10–15 years, to support future prevention
policies. GIBS is a project of the Global Influenza Initiative,
an expert scientific forum established to address the ongoing
problems related to influenza worldwide. To achieve this
objective, we contacted countries around the world during
the period June 2013 to February 2014, requesting access to
data from their national influenza surveillance systems. Here,
we compare four important epidemiological and virological
characteristics of influenza A and B in 26 countries: the
proportion of influenza B over all influenza cases; the
community impact of influenza B; the frequency of influenza
B vaccination mismatches; and the age distribution of
influenza A and B cases.
Materials and methods
Source of data
We contacted national influenza centers in 43 countries in
the Northern and Southern hemispheres and the intertrop-
ical belt; countries were selected to represent all World
Health Organization (WHO) influenza transmission zones.20
All countries were asked to make available data originating
from their national influenza surveillance system during
recent years (ideally from 2000–2013). Spreadsheet data
reporting templates were provided, along with instructions
on how to report data. Each participating country was asked
to provide the following:
1. Virological data: weekly number of influenza cases
reported by the national surveillance system, broken
down by age group (0–5, 6–35 months, 3–4, 5–17, 18–39,
40–64 and ≥65 years); virus type (A versus B); and virus
subtype [A(H1N1), A(H3N2), A(H1N1)pdm2009, A
(H1N2), A, unsubtyped] or lineage (B/Victoria, B/
Yamagata, B, not characterized).
2. Epidemiological data: weekly influenza-like illness (ILI)/
acute respiratory infection (ARI) rates per 100 000
population or 100 consultations (depending on what is
routinely available within each national surveillance
system).
For countries that extend over large areas, especially when
stretched across different climate zones (such as China and
Brazil), we asked for data stratified by region/province, if it
were available. All countries received a National Feedback
Report shortly after providing the data, so that they had the
opportunity to check the data they had sent. They were also
all asked to complete a short questionnaire on the main
features of their national influenza surveillance system (see
Table S1). The questionnaire included questions on the ILI/
ARI case definition in use; patients being sampled; repre-
sentativeness of data; methods used for identification and
characterization of influenza virus; and the population
denominator.
Epidemiological and virological indicators
Influenza epidemics usually occur between October of a
given year and April of the following year in countries in the
Northern Hemisphere, and between April and October of a
given year in the Southern Hemisphere, with greater
variability observed for countries situated near the tropics.17
Caini et al.
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For the purposes of this study, we define a season as being
the period between the first and last week of a given year (for
the tropics and the Southern Hemisphere) or between the
27th week of a given year and the 26th week of the following
year (for the Northern Hemisphere), so that each season
includes the whole period of increased influenza activity in
each country. For conciseness, when looking at “season
2005”, we refer to 2005–2006 for countries in the Northern
Hemisphere, and year 2005 for all other countries. For each
country, only the seasons with at least 50 influenza reported
cases and at least 20 weeks of data reporting were included in
the analysis.
Analyses were conducted for all countries and then
separately for countries situated in the Northern or Southern
Hemisphere or in the intertropical belt (defined as the
country centroid, when available, or the largest city being
located north of the Tropic of Cancer and south of the
Tropic of Capricorn).21
For each country and season, we calculated the percentage
of influenza cases that were due to influenza B virus and then
worked out its median value for countries in the Northern
and Southern hemispheres and in the intertropical belt.
Medians were compared using the Wilcoxon rank sum test.
We calculated the number of seasons that were dominated
by either lineage among those where there was a significant
circulation of influenza B (defined as the proportion of
influenza B being ≥20% of all influenza cases reported during
the season). For this analysis, we only considered seasons
where the proportion of influenza B cases characterized was
≥10%.
An influenza B vaccine mismatch was defined as a
mismatch between the influenza B lineage included in the
vaccine and the lineage that caused the majority (>50%) of
cases in a season with significant circulation of influenza B;
using this definition, we calculated the proportion of seasons
where a vaccine mismatch was observed. The information on
vaccine composition was obtained from the WHOWebsite.22
We calculated the percentage of vaccine mismatch according
to three alternative scenarios: (i) all tropical countries
situated north of the equator adopting the WHO recom-
mendations for the Northern Hemisphere, and vice versa; (ii)
all tropical countries using the Northern Hemisphere WHO
recommendation; or (iii) all tropical countries adopting the
Southern Hemisphere WHO recommendation.
Statistical analysis
To explore whether there was an association between the
magnitude of the influenza season and the proportion of
influenza cases due to B virus type, we obtained the country-
specific Z-score of the weekly ILI/ARI rate (defined as the
number of standard deviations above or below the country-
specific average of the ILI/ARI rate) and calculated the
Pearson’s correlation coefficient between its maximum value
and the proportion of influenza B cases during each season.
We hypothesized that a moderate-to-mild inverse correlation
would be seen between the proportion of influenza B and the
maximum weekly ILI/ARI rate in the Northern and Southern
hemispheres, as influenza A viruses cause most influenza
cases and are responsible for short and intense epidemics—
especially influenza A(H3N2)—compared with influenza B.
We calculated the percentage of influenza A and B cases in
each country in each of the following age categories: 0–4, 5–
17, 18–64 and ≥65 years; we tested whether the percentage of
influenza A versus B cases differed in each age group using a
chi-square test. When the exact age was available, we also
obtained virus type-specific median age and interquartile
range (IQR) and used the Wilcoxon rank sum test to detect
any differences in median age of influenza A versus B cases.
All analyses were performed using Stata version 11
(StataCorp LP, College Station, TX, USA) and Microsoft
Excel. All statistical tests were two-sided, and a P-value of
<005 was considered significant.
Results
Twenty-six countries joined the Global Influenza B Study
(Figure 1). China provided separate data for the northern
and southern parts of the country.23 Brazil provided data
stratified by its five administrative regions: north, north-east,
central-west, south-east and south; however, as results of the
analyses did not differ across regions, results for the whole
country are shown. Participating countries are distributed in
the Northern (n = 7) and Southern (n = 5) hemispheres and
in the intertropical belt (n = 14), cover 16 of the 18 WHO
influenza transmission zones,20 and account for around 37%
of the world’s population (Table 1).
The influenza surveillance systems of the participating
countries differ from each other (Table 1); in most cases,
however, they cover the whole country, sample both
outpatients and hospitalized patients, and send isolates to a
WHO collaborating center for reference. Most countries in
the Northern and Southern hemispheres had data on ILI
rates (ARI rates for Singapore), with a mixture of consul-
tation and population denominators, but many countries in
the tropics had no such data.
Overall, 935 673 influenza cases were reported to the
national influenza centers during 200 seasons between 2000
and 2013 (Table 2). Of these, 288 130 cases (308%) were
reported before the emergence of the 2009 A(H1N1)
pandemic influenza. Countries provided a median of seven
seasons, ranging from four seasons for Argentina, Costa Rica,
and Honduras, to 13 for New Zealand. The proportion of
influenza A cases subtyped was 651%, and 171% of
influenza B cases were characterized. The information on
age was available for 476% and 591% of influenza A and B
cases, respectively.
Results of the Global Influenza B Study
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The proportion of influenza cases due to type B virus was
<20% for 90 seasons, 20–50% for 82 seasons and ≥50% for
28 seasons; the median percentage was 226% (IQR 83–
377%). Figure 2 shows the distribution of seasons according
to the proportion of influenza cases caused by type B virus,
separately for countries situated in the Northern or Southern
Hemisphere or in the intertropical belt. The median
proportion of influenza B over all influenza seasons was
178% in the Southern Hemisphere (IQR 35–304%; 39
seasons), 243% in the intertropical belt (IQR 102–408%; 94
seasons), and 214% in the Northern Hemisphere (IQR 73–
380%; 67 seasons). The P-value for the comparison of the
median proportion of influenza B in the Southern Hemi-
sphere versus the intertropical belt was borderline significant
(007) and not significant for the other comparisons.
A measure of ILI (or ARI) rate was available for 106
seasons. The Spearman’s rank correlation coefficient for the
association between the proportion of influenza B during a
given season and the maximum ILI rate Z-score during the
same season was 031 in the Southern Hemisphere [95%
confidence interval (CI) 064 to 012; 23 seasons], 009 in
the intertropical belt (95% CI 043 to 026; 32 seasons), and
031 in the Northern Hemisphere (95% CI 054 to 004;
51 seasons) (Figure 3).
The proportion of influenza B cases that were character-
ized was ≥10% for 79 of the 200 seasons. If one assumes that
all countries in the intertropical belt used the WHO
recommendations for the hemisphere they are situated or
the WHO recommendation for the Southern Hemisphere, an
influenza B vaccine mismatch was seen in 19 of 79 seasons
(24–25%): 11 of 36 seasons in the Northern Hemisphere
(31%), six of 22 seasons in the Southern Hemisphere (27%),
and two of 21 seasons in the intertropical belt (10% or 14%)
(Table S2). If one assumes the WHO recommendation for
the Northern Hemisphere was followed, the results are very
similar: there were a total of 20 mismatches and three
mismatches for the intertropical belt countries.
Influenza B accounted for 20% or more of all influenza
cases during 50 of these 79 seasons: Victoria and Yamagata
lineages predominated in 32 (64%) and 18 (36%) seasons,
respectively. Also, the Victoria and Yamagata lineages often
co-circulate in the same season: in 16 of 50 seasons, both
lineages accounted for at least 20% of influenza B cases
(Table S2).
Table S3 presents the age distribution of A versus B
influenza cases in each country. A consistent finding across
most countries is a younger age for influenza B versus A
cases. In particular, there was a consistently higher propor-
tion of influenza B cases in the 5–17 years age group, and A
cases in the 18–64 years age group in Southern and Northern
Hemisphere countries (except South Africa, Brazil, Turkey,
and Ukraine) and in some countries of the intertropical belt
(Madagascar, Indonesia, Singapore, Costa Rica, Nicaragua,
Guatemala, and Vietnam). Influenza B cases were also
younger than A cases in Panama, El Salvador, and Honduras,
where there was a higher proportion of B cases among
patients aged 0–4 years. No differences in age distribution
were observed in Kenya, Cameroon, and the Ivory Coast;
these were the only countries where over 50% of all influenza
cases were aged ≤4 years. Finally, influenza A cases were
older than B cases in South Africa, Brazil, Turkey, and
Ukraine.
Discussion
The GIBS was conceived and implemented to obtain a better
understanding of the global epidemiology of influenza B,
with a particular focus on the tropics, which have been
Figure 1. Countries participating in the Global Influenza B Study. April 2014.
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relatively neglected by the research so far.8 Our main finding
was that influenza B is a common virus in the 21st century,
representing roughly 20% of all cases reported to national
influenza centers in 26 countries around the world during
2000–2013. Although the differences were not statistically
significant, there is some evidence of geographical variability
in the occurrence of influenza B around the world, with it
being most common in the tropics (median 243%) and least
common in the Southern Hemisphere (178%). We found
that influenza B rarely represented over 50% of flu cases
(once every seven seasons) and was generally associated with
lower rates of ILI in the Northern and (with borderline
significance) Southern hemispheres. We also found that there
was frequently a vaccine mismatch when influenza B
circulated in a country; this happened more often in the
Northern and Southern hemispheres compared with the
tropics. Finally, influenza B generally affected younger
persons than influenza A, with the former mainly affecting
school-aged children (aged 5–17 years) and the latter adults
(aged 18–64 years).
It is not yet clear what causes the differences in influenza
epidemiology (including timing, periodicity, and patterns of
transmission) in the tropics compared with the Southern and
Northern hemispheres.15 The non-significant higher propor-
tion of influenza B in the tropics may simply reflect the
relatively higher proportion of children, who are the most
affected age group, in most countries of this region compared
to the Northern and Southern hemispheres. It would,
however, be necessary to calculate age-specific incidence
rates of influenza to confirm or refute this hypothesis. Future
research should prioritize the study of influenza epidemiol-
ogy in this very populous area of the world, to optimize
prevention strategies and the composition and timing of
administration of the influenza vaccine.
The divergent results of the correlation between the
proportion of influenza B and peak of ILI rate mirror the
differences in influenza epidemiology in temperate and
tropical countries, with short epidemics and greater year-to-
year fluctuations for influenza A than B in the former4 and a
year-round influenza activity and higher average proportion
of B in the latter.17 It is usually not possible to predict with
reasonable accuracy the impact of the upcoming influenza
season based on historical data,24 and we have shown that
Victoria and Yamagata lineages often co-circulate in the same
season (Table S2). The frequency of vaccine mismatch has
been high in recent years (24–25% in the GIBS database),
but its potential consequences in terms of influenza cases,
influenza-related deaths, and economic costs are difficult to
estimate at the beginning of an influenza season. This has
important implications for vaccination strategies, including
the decision to adopt a quadrivalent influenza vaccine.10
Differences in the age distribution of influenza A versus B
patients across countries may be explained in a variety of
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Table 2. Influenza cases reported to the national influenza surveillance system of each participating country (from southern- to northernmost), and
percentages of cases that were subtyped, by virus type. The Global Influenza B Study
Country Seasons Influenza cases (n)
Influenza A
cases (n, %)
Influenza B
cases (n, %)
Influenza A
cases subtyped
(n, %)
Influenza B
cases
characterized
(n, %)
New Zealand 2000–2012 17 629 14 664 832 2965 168 11 670 796 2128 718
Chile 2008–2012 11 162 9983 894 1179 106 9488 950 646 548
Argentina (Santa Fe) 2009–2012 683 560 820 123 180 519 927 123 772
South Africa 2009–2013 1690 1098 650 592 350 1082 985 316 534
Australia 2001–2012 179 137 150 437 840 28 700 160 67 336 448 924 32
Madagascar 2002–2013 4068 2742 674 1326 326 2511 916 906 683
Brazil 2004–2012 3282 2399 731 883 269 0 00 0 00
Indonesia 2003–2007 3653 2339 640 1314 360 2313 989 662 504
Singapore 2007–2012 12 001 9690 807 2311 193 9690 1000 904 391
Kenya 2007–2012 6344 4852 765 1492 235 2933 604 144 97
Cameroon 2009–2013 733 504 688 229 312 504 1000 0 00
Ivory Coast 2007–2012 1581 975 617 606 383 867 889 0 00
Panama 2008–2013 2191 1868 853 323 147 1177 630 0 00
Costa Rica 2009–2012 6083 5569 916 514 84 5569 1000 0 00
Nicaragua 2007–2013 5677 4924 867 753 133 4427 899 0 00
El Salvador 2006–2013 2473 1965 795 508 205 1348 686 0 00
Honduras 2009–2012 1701 1528 898 173 102 1140 746 0 00
Guatemala 2006–2013 4360 3856 884 504 116 2441 633 0 00
Vietnam 2006–2013 8647 5636 652 3011 348 5630 999 0 00
Bhutan 2009–2013 1350 943 699 407 301 940 997 0 00
China (South) 2006–2012 122 215 86 305 706 35 910 294 76 792 890 14 606 407
Turkey 2006–2011 2155 1747 811 408 189 1597 914 384 941
China (North) 2005–2012 64 306 44 350 690 19 956 310 39 931 900 8040 403
Italy 2002–2012 23 340 21 702 930 1638 70 20 474 943 12 07
United States 2000–2012 441 547 371 050 840 70 497 160 216 990 585 0 00
Ukraine 2000–2012* 1389 1071 771 318 229 848 792 234 736
England 2003–2013 6276 4710 750 1566 250 4710 1000 619 395
Total 935 673 757 467 810 178 206 190 492 926 651 30 648 171
*Seasons 2001–2002 and 2003–2004 in the Ukraine were not included as the number of reported influenza cases was <50.
Figure 2. Distribution of influenza seasons by proportion of influenza B cases and geographical area (Southern Hemisphere, intertropical belt and
Northern Hemisphere). The Global Influenza B Study. April 2014. Purple bar presents median. Pink bars indicate 25% and 75% percentiles.
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ways, including differences in the age structure of the
population and in the national influenza surveillance systems
(e.g. whether the latter is mainly outpatient or hospital
based). Inequalities in access to health care by age or the
presence of comorbidities (children and older patients are
more likely to see a general practitioner or be taken to
hospital, and therefore be sampled, compared with adults
over 18 years of age) may also affect the age distribution of
influenza cases. In some countries (e.g. Cameroon and
Kenya), the lack of differences in age distribution may be due
to the small number of influenza cases in those age categories
where the differences are most frequently observed, that is,
5–17 and 18–64 years. Finally, the percentage of influenza A
cases due to seasonal and pandemic A(H1N1) and A(H3N2)
subtypes may differ across GIBS countries (especially as a
consequence of each country providing data for different
influenza seasons), so comparing B versus A as a whole may
be suboptimal – virus A subtypes may preferentially affect
people of different age groups.25 A more in-depth analysis of
age distribution across virus subtypes and lineages will be the
topic of a future GIBS publication.
The major limitation of our study lies in the differing
characteristics of the national influenza surveillance systems
of participating countries. In particular, the different defini-
tions of ILI (or ARI) that are in use and the differences in the
sources of patients included in the national databases
(outpatients, hospitalized patients, severe ARI patients)
may reduce the comparability of data across countries. Some
world regions (such as northern Africa and central Asia) are
currently not represented in our database, which somewhat
lessens the generalizability of our results. However, the GIBS
database already includes more than 900 000 influenza cases
and is still growing; in the future, therefore, it will be possible
to address specific questions on subsets of cases with
common characteristics. Large countries may have very
different epidemiological patterns at a regional level and
climatic characteristics, and in those cases, the lack of
stratified data may prevent the execution of analyses with the
required level of detail. For some countries, regional data are
available (e.g. Brazil and China), but in other countries, for
example the United States and Australia, it remains an issue.
Conclusion
This study indicates that it is important to take into
consideration influenza B in the epidemiology of seasonal
influenza, as it often co-circulates with influenza A and
accounts for roughly 20% of total cases in all regions of the
world, despite it rarely being the dominant strain. We believe
that global data on the epidemiology of influenza B, as those
produced by the GIBS, are needed on a continuing basis to
help optimize influenza prevention policies and determine
the public health value of introducing influenza vaccines
containing two B lineages. In particular, we recommend that
future studies exploit the potential of the GIBS database,
with its age-specific data, to assess the benefits of adopting
influenza vaccination in different regions of the world,
and tailor the vaccination campaigns to each country’s
requirements.
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